BS_ZVZDDW2G
pleomorphic xanthoastrocytoma(PXA)
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pleomorphic xanthoastrocytoma(PXA)
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pleomorphic xanthoastrocytoma(PXA)
- overall_survival_months
- 15.210249671484888
- age_years
- 3.704
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_VMQMGSJY | high-grade glioma | — | 0.943 |
| 2 | BS_769BDPDB | pilocytic astrocytoma | — | 0.937 |
| 3 | SJEPD009_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.937 |
| 4 | BS_0QYS36NR | Ependymoma NOS | — | 0.926 |
| 5 | BS_77CDMEY4 | Ganglioglioma | — | 0.925 |
| 6 | BS_55JW3HFM | Ganglioglioma | — | 0.923 |
| 7 | BS_EN2VK7NY | low-grade glioma | — | 0.922 |
| 8 | BS_0QYS36NR | EPN | EPN Tumor | 0.922 |
| 9 | R316 | — | — | 0.917 |
| 10 | BS_N1E0H8YQ | low-grade glioma | — | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.678 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.636 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.606 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.595 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.581 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.530 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.529 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.505 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.478 | Idelalisib | — uncovered |
| APOPTOSIS | 0.476 | Idelalisib | — uncovered |
| COAGULATION | 0.474 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.473 | Inavolisib | — uncovered |
| COMPLEMENT | 0.469 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.464 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.434 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.395 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.393 | Inavolisib | — uncovered |
| HYPOXIA | 0.392 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.386 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.375 | Inavolisib | — uncovered |